Proteins



HJ445A

Cat. No.: HY-163084 CAS No.: 3032441-59-8 Molecular Formula: $\mathsf{C}_{24}\mathsf{H}_{27}\mathsf{N}_7\mathsf{O}_2$ Molecular Weight: 445.52 Target: Others

Pathway: Others Storage: Powder

3 years 2 years

In solvent -80°C 6 months

-20°C

-20°C 1 month

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

DMSO: 100 mg/mL (224.46 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2446 mL	11.2228 mL	22.4457 mL
	5 mM	0.4489 mL	2.2446 mL	4.4891 mL
	10 mM	0.2245 mL	1.1223 mL	2.2446 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.5 mg/mL (5.61 mM); Clear solution; Need ultrasonic
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: 2.5 mg/mL (5.61 mM); Clear solution; Need ultrasonic
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (5.61 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	HJ445A is a potent MYOF inhibitor and binds to the MYOF-C2D domain with a K_D of 0.17 μ M. HJ445A potently repressed the proliferation of gastric cancer cells with IC ₅₀ values of 0.16 and 0.14 μ M in MGC803 and MKN45, respectively. HJ445A demonstrates superior antitumor efficacy in vivo and can be used for cancer research ^[1] .
IC ₅₀ & Target	IC50: MYOF ^[1]

[1]. Haijun Gu, et al. Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer. J Med Chem. 2023 Dec 6.
Caution: Product has not been fully validated for medical applications. For research use only.
Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com